Sign In
Buy ABCL
$9.34
+2.41 (+34.78%)
At Close: Aug 10, 2026
Investors Buy Large Volume of AbCellera Biologics Call Options (NASDAQ:ABCL)
01:21am, Tuesday, 11'th Aug 2026
AbCellera Biologics Inc. (NASDAQ: ABCL - Get Free Report) was the target of unusually large options trading on Monday. Stock investors purchased 16,666 call options on the company. This is an increase
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript
AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'
02:12pm, Monday, 10'th Aug 2026
AbCellera Biologics Inc. (NASDAQ:ABCL) announced positive top-line Phase 2 results from its Phase 1/2 trial evaluating ABCL635.
AbCellera Stock Jumps 33% on a Positive Menopause Trial
11:05am, Monday, 10'th Aug 2026
AbCellera (ABCL), a Vancouver clinical-stage antibody biotech, rose 33.19% intraday after its experimental menopause drug ABCL635 met both primary goals in a Ph
AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial
09:04am, Monday, 10'th Aug 2026
AbCellera Biologics NASDAQ: ABCL reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot flas
[url="]AbCellera[/url] (Nasdaq: ABCL) today announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an
AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise
07:13am, Monday, 10'th Aug 2026
AbCellera said Monday its experimental menopause treatment significantly reduced the frequency and severity of hot flashes in a mid-stage trial, sending its shares up 24% in premarke
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Aug. 10
AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call Transcript
12:20am, Thursday, 06'th Aug 2026
AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call Transcript
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates
09:36pm, Wednesday, 05'th Aug 2026
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.12 per share a year ago.
AbCellera Biologics Q2 Earnings Call Highlights
06:06pm, Wednesday, 05'th Aug 2026
AbCellera Biologics NASDAQ: ABCL said it expects to report top-line data “very soon” from its Phase I study of ABCL635, an antibody being evaluated for moderate-to-severe vasomotor symptoms, or ho
AbCellera Reports Q2 2026 Business Results
04:05pm, Wednesday, 05'th Aug 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q2 2026 Business Results.
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
07:00am, Wednesday, 29'th Jul 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions.
Playing The Biotech Breakout With Insiders
03:15pm, Thursday, 23'rd Jul 2026
Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking Al
